Jan. 23, 2019:

Big Ten investigators presented early efficacy results of the BTCRC-ESO14-012 study during the 2019 Gastrointestinal Cancers Symposium, Jan. 17-19 in San Francisco. Read More

Jan. 20, 2019:

In this month’s Across the Consortium, we highlight a variety of research initiatives — from genetic testing for quicker diagnosis to new projects that help us better understand biology in order to prevent and kill cancer faster — and we remember those who recently passed away and had a profound influence in cancer research and advocacy.

Read More

Jan. 10, 2019:

The Big Ten Cancer Research Consortium (Big Ten CRC) recently named Thomas G. Sors, PhD, assistant director of the Purdue Institute of Inflammation, Immunology and Infectious Disease (PI4D), to the Big Ten CRC Steering Committee, representing the Purdue University Center for Cancer Research.

The Big Ten CRC Steering Committee comprises one representative from each member institution and meets regularly to review activities and guide policies for the consortium. Read More

Dec. 20, 2018:

In this month’s Across the Consortium, we are inspired by Big Ten cancer researchers making significant discoveries in improving treatment and quality of life for cancer patients. We also recognize those who have received grants for their work.

Read More

Dec. 1, 2018:

Investigator Spotlight

Pavankumar Tandra, MBBS, Fred & Pamela Buffett Cancer Center (University of Nebraska)

Educational background

• MBBS: Osmania Medical School
• MRCGP: South East Scotland Deanery
• Fellowship (Hematology-Oncology): University of Nebraska Medical Center

Research interests

My research interests include tailoring the systemic therapies for early stage HER2-positive breast cancer. I believe we should do more studies in the neoadjuvant platform to assess the strengths of new targeted drugs, to identify biomarkers and minimize the toxicity from chemotherapy. It is very promising to see the new drugs studied in the metastatic setting showing positive results.
Read More

Nov. 20, 2018:

Kari Wisinski, MD, a breast cancer specialist with the UW Carbone Cancer Center, has been named to the Steering Committee of the Big Ten Cancer Research Consortium (Big Ten CRC).

In that role, she will serve as the University of Wisconsin-Madison representative, helping shape the research priorities of the Big Ten CRC. She currently is the co-chair of the consortium’s Breast Cancer Clinical Trial Working Group. Read More

Rutgers trial aims to demonstrate reduction in immune-related adverse events, while adding to anti-cancer immune effects for patients

Nov. 15, 2018:

BeyondSpring Inc. recently announced the opening of an investigator-initiated Phase 1 clinical trial with a triple combination therapy, consisting of BeyondSpring’s lead asset, plinabulin, and Bristol-Myers Squibb’s Opdivo (nivolumab) and Yervoy (ipilimumab) for the treatment of small-cell lung cancer (SCLC). The trial (BTCRC-LUN17-127), conducted through the Big Ten Cancer Research Consortium (Big Ten CRC), is currently enrolling subjects at Rutgers Cancer Institute of New Jersey. Jyoti Malhotra, MD, MPH, medical oncologist at Rutgers Cancer Institute, is the trial’s sponsor-investigator. The trial is expected to enroll approximately 15 patients in the Phase 1 portion of this Phase 1/2 combined study, and an additional 40 patients in the Phase 2 portion. Read More

Nov. 12, 2018:

In this month’s Across the Consortium, we focus on strategies Big Ten cancer centers are using to assist those who have difficulty finding resources for their cancer treatment or prevention. We also highlight some recent discoveries in several cancer types.

Read More

Nov. 1, 2018:

The Robert H. Lurie Comprehensive Cancer Center of Northwestern University (cancer.northwestern.edu), one of only 49 National Cancer Institute (NCI)-designated Comprehensive Cancer Centers in the nation, is dedicated to scientific discovery, advancing medical knowledge, providing compassionate, state-of-the-art cancer care, and training the next generation of clinicians and scientists. Outstanding basic, translational, and clinical research complements a full range of prevention, early detection, treatment, rehabilitation, and palliative care programs for all types of cancer. Read More

Oct. 23, 2018:

In this month’s Across the Consortium, we highlight the innovative work of our member cancer centers across a wide spectrum of cancer care: from prevention to new approaches to treatment, from bench science to survivorship. Catch the latest from each member cancer center in this month’s edition.

Read More